Table 3.
Group | UAER (µg/min) | 24 h Urinary Protein (mg/24 h) | UmALB (mg/L) | |||
---|---|---|---|---|---|---|
|
|
|
||||
Before Treatment | After Treatment | Before Treatment | After Treatment | Before Treatment | After Treatment | |
Early SGLT2-i group (n = 88) | 155.36±16.38 | 89.35±9.24* | 263.57±28.41 | 170.36±17.52* | 66.32±11.42 | 34.75±10.16* |
Late SGLT2-i group (n = 90) | 155.81±16.20 | 97.42±10.03* | 265.14±28.03 | 188.25±20.46* | 66.58±11.72 | 48.57±10.29* |
t | 0.184 | 5.580 | 0.371 | 6.260 | 0.147 | 9.023 |
P | 0.854 | < 0.001 | 0.711 | < 0.001 | 0.883 | < 0.001 |
P < 0.05 compared to pre-treatment within the same group;
UAER, urinary albumin excretion rate; UmALB, uric micro-albuminiuria; SGLT2-i, sodium-glucose cotransporter 2 inhibitor.